My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Clovis Oncology (CLVS)
NASDAQ:CLVS
CLVS nasdaq
United States
Clovis Oncology

Clovis Oncology Stock Analysis & Ratings

Clovis Oncology Stock Analysis Overview

Smart Score
4
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Clovis Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

CLVS

CLVS Stock Stats

Previous Close$3.16
Open$3.13
Bid2.9 x 100
Ask2.96 x 200
Today’s Range$2.93 - $3.275
52-Week Range$2.93 - $11.10
Volume5.17M
Average Volume3.05M
Market Cap$382.14M
Beta1.67
P/E Ratio-1.1
EPS-2.82
Earnings DateFeb 23, 2022

Company Description

Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Sector
Healthcare
Industry
Biotechnology
CEO
Patrick J. Mahaffy
Employees
429
ISIN
US1894641000
Address
5500 Flatiron Parkway, Boulder, CO, 80301, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

CLVS FAQ

What was Clovis Oncology’s price range in the past 12 months?
Clovis Oncology lowest stock price was $2.93 and its highest was $11.10 in the past 12 months.
    What is Clovis Oncology’s market cap?
    Clovis Oncology’s market cap is $382.14M.
      What is Clovis Oncology’s price target?
      The average price target for Clovis Oncology is $5.25. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $8.00 ,the lowest forecast is $3.00. The average price target represents 78.57% Increase from the current price of $2.94.
        What do analysts say about Clovis Oncology?
        Clovis Oncology’s analyst rating consensus is a ‘Hold. This is based on the ratings of 3 Wall Streets Analysts.
          When is Clovis Oncology’s upcoming earnings report date?
          Clovis Oncology’s upcoming earnings report date is Feb 23, 2022 which is in 83 days.
            How were Clovis Oncology’s earnings last quarter?
            Clovis Oncology released its earnings results on Nov 03, 2021. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.082.
              Is Clovis Oncology overvalued?
              According to Wall Street analysts Clovis Oncology’s price is currently Undervalued.
                Does Clovis Oncology pay dividends?
                Clovis Oncology does not currently pay dividends.
                What is Clovis Oncology’s EPS estimate?
                Clovis Oncology’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Clovis Oncology have?
                Clovis Oncology has 129,980,000 shares outstanding.
                  What happened to Clovis Oncology’s price movement after its last earnings report?
                  Clovis Oncology reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -3.992%.
                    Which hedge fund is a major shareholder of Clovis Oncology?
                    Among the largest hedge funds holding Clovis Oncology’s share is Gamco Investors, Inc. ET AL. It holds Clovis Oncology’s shares valued at 875K.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis